alendronate has been researched along with Osteolysis in 45 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether alendronate alters the pseudomembrane inflammatory cytokine profile in patients with established aseptic osteolysis." | 9.14 | Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis. ( Holt, G; Meek, RM; Reilly, J, 2010) |
| "We investigated the effects of locally and systemically administered alendronate on wear debris-induced osteolysis in vivo." | 7.76 | The effects of local and systemic alendronate delivery on wear debris-induced osteolysis in vivo. ( Cai, XZ; Li, R; Yan, SG; Zhu, FB; Zhu, HX, 2010) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 7.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| "A rat model was used to study the efficacy of alendronate therapy in inhibition of particle-induced periprosthetic osteolysis." | 7.71 | Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. ( Barmada, R; Gonzalez, MH; Sladek, E; Thadani, PJ; Waxman, B, 2002) |
| "The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla." | 7.70 | Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000) |
| "Acidosis was induced for 14 days and alendronate was administered every 3 days for the acidosis+BPP group." | 5.91 | Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice. ( Deymier, A; Moody, M; Schmidt, TA; Trivedi, R, 2023) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 5.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "We investigated the effects of locally and systemically administered alendronate on wear debris-induced osteolysis in vivo." | 3.76 | The effects of local and systemic alendronate delivery on wear debris-induced osteolysis in vivo. ( Cai, XZ; Li, R; Yan, SG; Zhu, FB; Zhu, HX, 2010) |
| " We have recently developed biodegradable, biocompatible nanoparticles (NP) made of a conjugate between poly (D,L-lactide-co-glycolic) acid and alendronate, suitable for systemic administration, and directly targeting the site of tumor-induced osteolysis." | 3.76 | Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. ( Angelucci, A; Avnet, S; Baldini, N; Capulli, M; Castelli, F; Cenni, E; Del Fattore, A; Fotia, C; Giunti, A; Granchi, D; Micieli, D; Pignatello, R; Rucci, N; Salerno, M; Teti, A; Zini, N, 2010) |
| "The aim of this study was to investigate the drug distribution in ultra-high molecular weight polyethylene (UHMWPE) loaded with alendronate sodium (ALN), which was developed to treat particle-induced osteolysis after artificial joint replacements, since the drug distribution in UHMWPE could play a key role in controlling drug release." | 3.75 | Time-of-flight secondary ion mass spectrometry study on the distribution of alendronate sodium in drug-loaded ultra-high molecular weight polyethylene. ( Ge, X; Leng, Y; Liu, X; Lu, X; Qu, S, 2009) |
| "Alendronate could prevent particle-induced osteolysis." | 3.74 | [Experiment study of alendronate in the prevention and treatment of aseptic loosening of prosthesis]. ( Chen, M; Fang, ZH; Kan, WS; Zheng, Q, 2008) |
| " Because this difference has been attributed to the antiapoptotic inflammatory signals that protect osteoclasts from BP-induced apoptosis, but not RANK antagonists, we tested the hypothesis that osteoprotegerin (OPG) is more effective in preventing wear debris-induced osteolysis than zoledronic acid (ZA) or alendronate (Aln) in the murine calvaria model using in vivo micro-CT and traditional histology." | 3.74 | Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. ( Awad, HA; Bechtold, CD; Bukata, SV; Hock, C; Ito, H; Nakamura, T; O'Keefe, RJ; Proulx, ST; Schwarz, EM; Tsutsumi, R, 2008) |
| "Alendronate has been shown to prevent osteolysis in a canine total hip arthroplasty (THA) model." | 3.73 | Effect of oral alendronate on net bone ingrowth into canine cementless total hips. ( Bragdon, CR; Doherty, AM; Harris, WH; Jasty, M; Rubash, H, 2005) |
| " In the present report we address, in a single in vivo mouse model, the effects the bisphosphonate alendronate has on bone cancer pain, bone remodeling and tumor growth and necrosis." | 3.72 | Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. ( De Felipe, C; Ghilardi, JR; Kuskowski, MA; Luger, NM; Mach, DB; Mantyh, PW; Peters, CM; Röhrich, H; Sabino, MA; Schwei, MJ; Sevcik, MA, 2004) |
| "A rat model was used to study the efficacy of alendronate therapy in inhibition of particle-induced periprosthetic osteolysis." | 3.71 | Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. ( Barmada, R; Gonzalez, MH; Sladek, E; Thadani, PJ; Waxman, B, 2002) |
| "The bisphosphonate drug alendronate was used to suppress bone remodelling and tumour osteolysis as a palliative treatment for two dogs with osteosarcoma, one of the tibia and one of the maxilla." | 3.70 | Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. ( Muir, P; Pead, MJ; Sturgeon, C; Tomlin, JL, 2000) |
| "Sarcoidosis is a multisystem disease of unknown origin." | 2.47 | Rare localizations of bone sarcoidosis: two case reports and review of the literature. ( Bargagli, E; Bertelli, P; Gonnelli, S; Olivieri, C; Penza, F; Rottoli, P; Volterrani, L, 2011) |
| "Acidosis was induced for 14 days and alendronate was administered every 3 days for the acidosis+BPP group." | 1.91 | Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice. ( Deymier, A; Moody, M; Schmidt, TA; Trivedi, R, 2023) |
| "Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption." | 1.31 | Effects of alendronate on particle-induced osteolysis in a rat model. ( Allen, MJ; Bostrom, MP; Millett, PJ, 2002) |
| "This osteolysis was evaluated by measuring the increased area of bone resorption in reduced opacity to radiograph and histologic study." | 1.28 | Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. ( Koiso, K; Miyagawa, I; Nemoto, R; Satou, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (15.56) | 18.2507 |
| 2000's | 19 (42.22) | 29.6817 |
| 2010's | 17 (37.78) | 24.3611 |
| 2020's | 2 (4.44) | 2.80 |
| Authors | Studies |
|---|---|
| Larrañaga-Vera, A | 2 |
| Toti, KS | 2 |
| Flatow, JS | 2 |
| Haraczy, AJ | 2 |
| Warnick, E | 2 |
| Rao, H | 2 |
| Gao, ZG | 2 |
| Sussman, SM | 2 |
| Mediero, A | 2 |
| Leucht, P | 2 |
| Jacobson, KA | 2 |
| Cronstein, BN | 2 |
| Moody, M | 1 |
| Schmidt, TA | 1 |
| Trivedi, R | 1 |
| Deymier, A | 1 |
| Campbell, GM | 1 |
| Tower, RJ | 1 |
| Damm, T | 1 |
| Kneissl, P | 1 |
| Rambow, AC | 1 |
| Schem, C | 1 |
| Tiwari, S | 1 |
| Glüer, CC | 1 |
| Geng, T | 1 |
| Chen, X | 1 |
| Zheng, M | 1 |
| Yu, H | 1 |
| Zhang, S | 1 |
| Sun, S | 1 |
| Guo, H | 1 |
| Jin, Q | 1 |
| Wang, Y | 1 |
| Huang, Q | 1 |
| He, X | 1 |
| Chen, H | 1 |
| Zou, Y | 1 |
| Li, Y | 1 |
| Lin, K | 1 |
| Cai, X | 1 |
| Xiao, J | 1 |
| Zhang, Q | 1 |
| Cheng, Y | 1 |
| Prada García, C | 1 |
| Rodríguez Prieto, MÁ | 1 |
| Hamada, H | 1 |
| Matsuo, A | 1 |
| Koizumi, T | 1 |
| Satomi, T | 1 |
| Chikazu, D | 1 |
| Liu, Y | 2 |
| Shi, F | 1 |
| Gong, K | 1 |
| Zhi, W | 1 |
| Weng, J | 2 |
| Qu, S | 3 |
| Arabmotlagh, M | 1 |
| Pilz, M | 1 |
| Warzecha, J | 1 |
| Rauschmann, M | 1 |
| Chen, M | 1 |
| Zheng, Q | 1 |
| Fang, ZH | 1 |
| Kan, WS | 1 |
| Holt, G | 1 |
| Reilly, J | 1 |
| Meek, RM | 1 |
| Liu, X | 2 |
| Lu, X | 1 |
| Ge, X | 1 |
| Leng, Y | 1 |
| Bargagli, E | 1 |
| Olivieri, C | 1 |
| Penza, F | 1 |
| Bertelli, P | 1 |
| Gonnelli, S | 1 |
| Volterrani, L | 1 |
| Rottoli, P | 1 |
| Zhu, FB | 1 |
| Cai, XZ | 2 |
| Yan, SG | 2 |
| Zhu, HX | 1 |
| Li, R | 1 |
| Chiu, CT | 1 |
| Chiang, WF | 1 |
| Chuang, CY | 1 |
| Chang, SW | 1 |
| Kuijpers, SC | 1 |
| van Roessel, EW | 1 |
| van Merkesteyn, JP | 1 |
| Salerno, M | 1 |
| Cenni, E | 1 |
| Fotia, C | 1 |
| Avnet, S | 1 |
| Granchi, D | 1 |
| Castelli, F | 1 |
| Micieli, D | 1 |
| Pignatello, R | 1 |
| Capulli, M | 1 |
| Rucci, N | 1 |
| Angelucci, A | 1 |
| Del Fattore, A | 1 |
| Teti, A | 1 |
| Zini, N | 1 |
| Giunti, A | 1 |
| Baldini, N | 1 |
| Zeng, Y | 1 |
| Lai, O | 1 |
| Shen, B | 1 |
| Yang, J | 1 |
| Zhou, Z | 1 |
| Kang, P | 1 |
| Pei, F | 1 |
| Lin, T | 1 |
| Wang, C | 1 |
| Niu, S | 1 |
| Cao, X | 1 |
| Zhang, Y | 1 |
| Zhu, Q | 1 |
| Zhu, J | 1 |
| O'Ryan, FS | 1 |
| Lo, JC | 1 |
| Bai, Y | 1 |
| Fu, R | 1 |
| Duan, K | 1 |
| Ogata, A | 1 |
| Kitano, M | 1 |
| Hashimoto, N | 1 |
| Iwasaki, T | 1 |
| Hamano, T | 1 |
| Kakishita, E | 1 |
| Nehme, A | 1 |
| Maalouf, G | 1 |
| Tricoire, JL | 1 |
| Giordano, G | 1 |
| Chiron, P | 1 |
| Puget, J | 1 |
| Astrand, J | 1 |
| Aspenberg, P | 1 |
| Sevcik, MA | 1 |
| Luger, NM | 1 |
| Mach, DB | 1 |
| Sabino, MA | 1 |
| Peters, CM | 1 |
| Ghilardi, JR | 1 |
| Schwei, MJ | 1 |
| Röhrich, H | 1 |
| De Felipe, C | 1 |
| Kuskowski, MA | 1 |
| Mantyh, PW | 1 |
| Bragdon, CR | 1 |
| Doherty, AM | 1 |
| Jasty, M | 1 |
| Rubash, H | 1 |
| Harris, WH | 1 |
| Samdancioglu, S | 1 |
| Calis, S | 1 |
| Sumnu, M | 1 |
| Atilla Hincal, A | 1 |
| Ponte Fernández, N | 1 |
| Estefania Fresco, R | 1 |
| Aguirre Urizar, JM | 1 |
| Letonturier, P | 1 |
| Tsutsumi, R | 1 |
| Hock, C | 1 |
| Bechtold, CD | 1 |
| Proulx, ST | 1 |
| Bukata, SV | 1 |
| Ito, H | 1 |
| Awad, HA | 1 |
| Nakamura, T | 1 |
| O'Keefe, RJ | 1 |
| Schwarz, EM | 2 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Shanbhag, AS | 1 |
| Hasselman, CT | 1 |
| Rubash, HE | 1 |
| Greenwald, RA | 1 |
| Stein, B | 1 |
| Miller, F | 1 |
| Lombardi, A | 1 |
| Antoniou, J | 1 |
| Huk, O | 1 |
| Zukor, D | 1 |
| Eyre, D | 1 |
| Alini, M | 1 |
| Tomlin, JL | 1 |
| Sturgeon, C | 1 |
| Pead, MJ | 1 |
| Muir, P | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Benz, EB | 1 |
| Lu, AP | 1 |
| Goater, JJ | 1 |
| Mollano, AV | 1 |
| Rosier, RN | 1 |
| Puzas, JE | 1 |
| Okeefe, RJ | 1 |
| Frenkel, SR | 1 |
| Jaffe, WL | 1 |
| Valle, CD | 1 |
| Jazrawi, L | 1 |
| Maurer, S | 1 |
| Baitner, A | 1 |
| Wright, K | 1 |
| Sala, D | 1 |
| Hawkins, M | 1 |
| Di Cesare, PE | 1 |
| Thadani, PJ | 1 |
| Waxman, B | 1 |
| Sladek, E | 1 |
| Barmada, R | 1 |
| Gonzalez, MH | 1 |
| Millett, PJ | 1 |
| Allen, MJ | 1 |
| Bostrom, MP | 1 |
| Nemoto, R | 3 |
| Satou, S | 2 |
| Mochizuki, T | 1 |
| Okabe, K | 1 |
| Miyagawa, I | 1 |
| Koiso, K | 2 |
| Sato, S | 1 |
| Nishijima, Y | 1 |
| Miyakawa, I | 1 |
| Harada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alendronate and Osteolysis
| Article | Year |
|---|---|
Rare localizations of bone sarcoidosis: two case reports and review of the literature.
Topics: Alendronate; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Fema | 2011 |
A systematic review assessing the effectiveness of alendronate in reducing periprosthetic bone loss after cementless primary THA.
Topics: Alendronate; Arthroplasty, Replacement, Hip; Bone Cements; Bone Density; Bone Density Conservation A | 2011 |
Bisphosphonates and oral pathology I. General and preventive aspects.
Topics: Administration, Oral; Alendronate; Antibiotic Prophylaxis; Bone Density Conservation Agents; Bone Re | 2006 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
4 trials available for alendronate and Osteolysis
| Article | Year |
|---|---|
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Alendronate; Arthroplasty, Replacement, H | 2009 |
Effect of alendronate on pseudomembrane cytokine expression in patients with aseptic osteolysis.
Topics: Aged; Aged, 80 and over; Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agen | 2010 |
[Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study].
Topics: Alendronate; Arthroplasty, Replacement, Hip; Bone Density; Calcium; Double-Blind Method; Female; Hum | 2003 |
Treatment of Paget's disease of bone with alendronate.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid; | 1999 |
37 other studies available for alendronate and Osteolysis
| Article | Year |
|---|---|
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Novel alendronate-CGS21680 conjugate reduces bone resorption and induces new bone formation in post-menopausal osteoporosis and inflammatory osteolysis mouse models.
Topics: Alendronate; Animals; Bone Resorption; Disease Models, Animal; Female; Humans; Mice; Mice, Inbred C5 | 2022 |
Administration of alendronate exacerbates ammonium chloride-induced acidosis in mice.
Topics: Acidosis; Alendronate; Ammonium Chloride; Animals; Diphosphonates; Mice; Osteolysis; Renal Insuffici | 2023 |
Tracking the Progression of Osteolytic and Osteosclerotic Lesions in Mice Using Serial In Vivo μCT: Applications to the Assessment of Bisphosphonate Treatment Efficacy.
Topics: Alendronate; Animals; Bone Resorption; Cell Line, Tumor; Diphosphonates; Disease Progression; Female | 2018 |
Effects of strontium ranelate on wear particle‑induced aseptic loosening in female ovariectomized mice.
Topics: Aged; Alendronate; Animals; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Hum | 2018 |
Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cells, Cultured; Combin | 2018 |
Submandibular cutaneous fistula.
Topics: Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Con | 2013 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Ass | 2014 |
Study on critical-sized ultra-high molecular weight polyethylene wear particles loaded with alendronate sodium: in vitro release and cell response.
Topics: Alendronate; Animals; Cell Proliferation; Chemotaxis; Coculture Techniques; Cytokines; Drug Carriers | 2017 |
[Experiment study of alendronate in the prevention and treatment of aseptic loosening of prosthesis].
Topics: Alendronate; Animals; Cytokines; Female; Humans; Joint Prosthesis; Joints; Male; Osteolysis; Prosthe | 2008 |
Time-of-flight secondary ion mass spectrometry study on the distribution of alendronate sodium in drug-loaded ultra-high molecular weight polyethylene.
Topics: Alendronate; Arthroplasty, Replacement; Biocompatible Materials; Drug Delivery Systems; Hardness Tes | 2009 |
The effects of local and systemic alendronate delivery on wear debris-induced osteolysis in vivo.
Topics: Absorptiometry, Photon; Alendronate; Animals; Biomechanical Phenomena; Biopsy; Bone Cements; Bone De | 2010 |
Resolution of oral bisphosphonate and steroid-related osteonecrosis of the jaw--a serial case analysis.
Topics: Actinomycosis; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bo | 2010 |
Unusual case of a conservatively treated pathological fracture after sequestrectomy in a patient with long-term oral bisphosphonate use.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Di | 2011 |
Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.
Topics: Acid Phosphatase; Alendronate; Animals; Antineoplastic Agents; Biological Transport; Bone Density Co | 2010 |
Identifying multiple reports from the same study.
Topics: Alendronate; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Humans; Osteolysis | 2011 |
The inhibitory effect of alendronate-hydroxyapatite composite coating on wear debris-induced peri-implant high bone turnover.
Topics: Alendronate; Animals; Bone Density; Cytokines; Durapatite; Male; Models, Animal; Orthopedics; Osteol | 2013 |
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antirheumatic Age | 2012 |
Study on in vitro release and cell response to alendronate sodium-loaded ultrahigh molecular weight polyethylene loaded with alendronate sodium wear particles to treat the particles-induced osteolysis.
Topics: Alendronate; Animals; Coculture Techniques; Macrophages; Mice; Osteoblasts; Osteolysis; Particle Siz | 2013 |
Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Topics: Adult; Alendronate; Biomarkers; Bone Diseases; Drug Therapy, Combination; Female; Humans; Multiple M | 2002 |
Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening.
Topics: Administration, Topical; Alendronate; Animals; Disease Models, Animal; Male; Movement; Osteolysis; P | 2004 |
Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis.
Topics: Activating Transcription Factor 3; Alendronate; Animals; Behavior, Animal; Biomarkers, Tumor; Bone N | 2004 |
Effect of oral alendronate on net bone ingrowth into canine cementless total hips.
Topics: Administration, Oral; Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Development; Bone R | 2005 |
Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis.
Topics: Alendronate; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Chitosan; Drug Implants; E | 2006 |
[Questions and answers about bisphosphonates].
Topics: Administration, Oral; Age Factors; Alendronate; Bone Density; Bone Density Conservation Agents; Bone | 2007 |
Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT.
Topics: Alendronate; Animals; Biocompatible Materials; Bone Density Conservation Agents; Diphosphonates; Dis | 2008 |
The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model.
Topics: Alendronate; Animals; Awards and Prizes; Bone Resorption; Dinoprostone; Dogs; Evaluation Studies as | 1997 |
Rapid skeletal turnover and hypercalcemia associated with markedly elevated interleukin-6 levels in a young black man.
Topics: Adult; Alendronate; Alkaline Phosphatase; Black People; Bone and Bones; Bone Remodeling; Collagen; C | 1998 |
Collagen crosslinked N-telopeptides as markers for evaluating particulate osteolysis: a preliminary study.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Resorption; Collagen; Creatinine; Female; Humans; Male; M | 2000 |
Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Remodeling; Dog Diseases; Dogs; Male; Osteolysis; Osteosa | 2000 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |
Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
Topics: Alendronate; Animals; Arthritis; Arthroplasty; Cell Division; Disease Models, Animal; Female; Male; | 2000 |
The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model.
Topics: Alendronate; Animals; Arthroplasty, Replacement, Hip; Bone Plates; Bone Remodeling; Disease Models, | 2001 |
Inhibition of particulate debris-induced osteolysis by alendronate in a rat model.
Topics: Alendronate; Animals; Disease Models, Animal; Male; Osteolysis; Polymethyl Methacrylate; Prostheses | 2002 |
Effects of alendronate on particle-induced osteolysis in a rat model.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Injections, Intra-Art | 2002 |
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcitonin; Cyclosporine; Diphosphonates; Fem | 1992 |
Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Female; Mice; Mice, Inbred C3H; Necrosis; Neop | 1991 |
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude | 1990 |